Fig. 6

Construction and validation of LHRS. A Flow chart of the construction and validation of prognostic signature for HCC. B The overlap of the results of univariate Cox regression analysis across three training cohorts. Protective and risk genes were identified, respectively. C The numbers of iterations with significant results (P < 0.05) for 287 genes from preliminary screening. D Functional similarity of genes in LHRS. Functional annotation was added based on the information from KEGG pathway metadata. E The results of univariate Cox regression analysis of LHRS across training and testing cohorts. F Comparison of mean time-dependent AUC values between LHRS and six previously published signatures in training and testing cohorts. G Comparison of IHS of signature genes between LHRS and other six published signatures. H The distribution of LHRS scores of 75 multi-regional tumor samples. Each point indicates a single region and the vertical lines represent the distribution range of LHRS scores for each individual. All samples were divided into low-ITH and high-ITH groups based on the median value. Blue nodes represent the tumors with all regions classified into the low-ITH group; red nodes represent the tumors with all regions classified into the high-ITH group; grey nodes represent the tumors with both low-ITH and high-ITH regions. I Comparison of the percentages of patients who were classified as concordant low risk (blue), concordant high risk (red) or discordant (gray) between LHRS and other six published signatures. A lower discordant proportion indicates a better performance. J Patient group overall ratio (PGOR) curves of LHRS (solid line) and other six signatures (dashed line). K Comparison of AUC values of PGOR curves between LHRS and other six signatures